Indoco Remedies Reports ₹485 Crore Revenue in Q2 FY26; Net Loss Narrows to ₹8 Crore

Indoco Remedies announced its Q2 FY26 results on November 6, reporting improved earnings and higher revenue compared to the same quarter last year.

Key Financial Highlights for Q2 FY26

·       Net Loss: ₹8 crore vs ₹9.6 crore in Q2 FY25

·       Revenue: ₹485 crore, up 12% YoY from ₹433 crore

·       EBITDA: ₹43.4 crore, up 6.6% YoY from ₹41 crore

·       EBITDA Margin: 9% vs 9.4% in Q2 FY25

Margins contracted slightly despite higher revenue and EBITDA growth.

Q1 FY26 Performance Recap

·       Net Loss: ₹35.6 crore vs net profit of ₹2.6 crore in Q1 FY25

·       Revenue: ₹438 crore, up 1.5% YoY

·       EBITDA: ₹17.8 crore, down 62.8% YoY from ₹47.8 crore

·       EBITDA Margin: 4.06% vs 11.08% in Q1 FY25

The sharp decline in Q1 EBITDA and margins contrasts with the recovery seen in Q2.

Operational Outlook

The company highlighted efforts to stabilise operations and improve profitability through cost optimisation and portfolio expansion. Sequential improvement in EBITDA indicates progress toward operational recovery.

Indoco Remedies Share Price Performance

On November 6, 2025, Indoco Remedies share price opened at ₹271.20, compared to the previous close of ₹270.95. During the session, the stock touched a high of ₹288.00 and a low of ₹266.60. At 1:51 PM IST, it was trading at ₹268.95, down by 0.74%.

The stock recorded a traded volume of 4.33 lakh shares and a traded value of ₹11.86 crore on the NSE. The market capitalisation stood at ₹2,481.01 crore. Over the past 52 weeks, Indoco Remedies has hit a high of ₹355.00 and a low of ₹190.00. The P/E ratio for the stock is -34.36.

Read More: Zepto Launches 10-Minute Medicine Delivery.

Conclusion

Indoco Remedies narrowed its net loss and posted double-digit revenue growth in Q2 FY26, supported by improved EBITDA performance. While margins remain under pressure, sequential recovery signals progress toward stabilising operations.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.